Riskpilot← Back to searchSign inGet full accessValiderma AB
ABActiveOrg 5592043276Ringgatan 41 AGeneral medical practice activities · NACE 8621Est. 20190 employees
Revenue 2025
SEK -1
EBITDA margin
535100.0%
+3% vs 2024
Equity ratio
92.7%
Financial strength
Net profit 2025
SEK -5K
-61% vs 2024
| Revenue | SEK -1 | — |
| EBITDA | SEK -5K | +3% |
| Net profit | SEK -5K | -61% |
| Total assets | SEK 57K | -73% |
| Equity | SEK 53K | -74% |
| Employees | 0 | — |
Legal name
Validerma AB
Org number
5592043276
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
2 maj 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är sjukvård, medicinsk konsultation, värdepappershandel, handel och förvaltning av fastigheter och därmed förenlig verksamhet.
Address
Ringgatan 41 A
Email
kasra_vali@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 78 | 0 | 0 | 0 | −0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 65 | −12 | −8 | −5 | −5 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 65 | −12 | −8 | −5 | −5 |
| Net financials | — | 0 | 2 | 3 | 1 |
| Profit before tax | 65 | −12 | −6 | −3 | −5 |
| Tax | −13 | — | — | — | — |
| Net profit | 52 | −12 | −6 | −3 | −5 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 247 | 219 | 215 | 212 | 57 |
| Equity | 229 | 217 | 211 | 208 | 53 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 18 | 2 | 4 | 4 | 4 |
| Total debt | 18 | 2 | 4 | 4 | 4 |
EBITDA margin
-535100.0%
This company
15.8%
Market median
-3386809% vs market
20212025
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20212025
Return on equity
-9.0%
This company
18.4%
Market median
-149% vs market
20212025
Net profit margin
-479200.0%
This company
8.1%
Market median
-5916149% vs market
20212025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Validerma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Vali Jalali | Deputy Board Member | 0 companies |
| Kasra Vali Jalali | Board of Directors | 0 companies |